{"result": "(\"entity\"<|>COX MODEL<|>EVENT<|>A statistical method used to estimate the hazard ratio (HR) in the study, indicating the effect of corticosteroid therapy on vasopressor therapy withdrawal)\n##\n(\"entity\"<|>PLACEBO GROUP<|>ORGANIZATION<|>A group of patients in the study who received a placebo treatment for comparison with the corticosteroid group)\n##\n(\"entity\"<|>CORTICOSTEROID GROUP<|>ORGANIZATION<|>A group of patients in the study who received corticosteroid therapy to assess its effects on septic shock)\n##\n(\"entity\"<|>HYDROCORTISONE<|>ORGANIZATION<|>A natural hormone used in the study as part of replacement therapy to treat septic shock and relative adrenal insufficiency)\n##\n(\"entity\"<|>FLUDROCORTISONE<|>ORGANIZATION<|>A synthetic corticosteroid used in combination with hydrocortisone in the study to treat septic shock and relative adrenal insufficiency)\n##\n(\"entity\"<|>SEPTIC SHOCK<|>EVENT<|>A severe medical condition being studied, characterized by a significant drop in blood pressure and organ dysfunction due to infection)\n##\n(\"entity\"<|>RELATIVE ADRENAL INSUFFICIENCY<|>EVENT<|>A condition in which the adrenal glands do not produce adequate amounts of hormones, particularly during stress, and a focus of the study)\n##\n(\"entity\"<|>ICU<|>GEO<|>Intensive Care Unit, where patients with severe conditions like septic shock are treated)\n##\n(\"entity\"<|>9TH INTERNATIONAL CONFERENCE ON HARMONIZATION<|>EVENT<|>A conference that provided guidelines for the statistical analysis used in the study)\n##\n(\"relationship\"<|>COX MODEL<|>CORTICOSTEROID GROUP<|>The Cox model was used to estimate the hazard ratio for the corticosteroid group's effect on vasopressor therapy withdrawal<|>8)\n##\n(\"relationship\"<|>PLACEBO GROUP<|>CORTICOSTEROID GROUP<|>The placebo group served as a control to compare the effects of corticosteroid therapy in the study<|>9)\n##\n(\"relationship\"<|>HYDROCORTISONE<|>FLUDROCORTISONE<|>Hydrocortisone and fludrocortisone were used together in replacement therapy for treating septic shock<|>9)\n##\n(\"relationship\"<|>SEPTIC SHOCK<|>RELATIVE ADRENAL INSUFFICIENCY<|>The study focused on patients with septic shock and relative adrenal insufficiency to assess the benefits of replacement therapy<|>8)\n##\n(\"relationship\"<|>ICU<|>SEPTIC SHOCK<|>Patients with septic shock were treated in the ICU as part of the study<|>7)\n##\n(\"relationship\"<|>9TH INTERNATIONAL CONFERENCE ON HARMONIZATION<|>COX MODEL<|>The conference provided guidelines for the statistical analysis, including the use of the Cox model<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: The HR estimated using a Cox model was 1.91 (95% CI, 1.29-2.84; P = .001) (Figure 3A). At day 28, vasopressor therapy had been withdrawn in 46 patients (40%) in the placebo group and in 65 patients (57%) in the corticosteroid group.\n\nResponders\nThe median time-to-vasopressor-therapy withdrawal was 7 days in the placebo group and 9 days in the corticosteroid group. The proportionality assumption was not supported for the Cox model and comparison of time-to-vasopressor-therapy withdrawal distributions was performed using a log-rank test (P = .49, Figure 3B). At day 28, vasopressor therapy had been withdrawn in 18 patients (53%) in the placebo group and in 18 patients (50%) in the corticosteroid group.\n\nAll Patients\nThe median time to vasopressor therapy withdrawal was 9 days in the placebo group and 7 days in the corticosteroid group. The HR estimated using a Cox model was 1.54 (95% CI, 1.10-2.16; P = .01; Figure 3C). At day 28, vasopressor therapy had been withdrawn in 64 patients (43%) in the placebo group and in 83 patients (55%) in the corticosteroid group.\n\nAdverse Events\nThere were no significant differences between the 2 groups in the rates of adverse events possibly related to corticosteroids or vasopressors, or related to ICU invasive procedures (Table 5).\n\nComment\nWe found that a 7-day replacement therapy with hydrocortisone (50 mg intravenous bolus every 6 hours) and fludrocortisone (50 Âµg tablet once daily) significantly reduced 28-day mortality and duration of vasopressor administration in all patients with septic shock, in particular those with relative adrenal insufficiency. In addition, among the latter, corticosteroid therapy significantly reduced mortality during both ICU and hospital stays, and tended to reduce 1-year mortality. Our results indicate that, in this population, 1 additional life could be saved at day 28 for every 7 patients treated with corticosteroids. Replacement therapy had no significant effect on the same variables in patients who had septic shock without relative adrenal insufficiency. If the power to detect differences in responders was lower than that in nonresponders due to the lower proportion of responders, it should be observed that no tendency toward efficacy (or deleterious effect) was observed in responders for any of the above mentioned variables. These results confirm the hypothesis on which the study was planned that patients with septic shock with relative adrenal insufficiency could benefit from replacement therapy.\n\nOur results are consistent with a study of healthy volunteers challenged with endotoxin27 and with 2 studies of patients with septic shock,12,13 that showed that low doses of hydrocortisone can restore vascular responsiveness to catecholamines. Our results are also consistent with those of 2 small trials showing that replacement therapy with hydrocortisone reduces the time-to-vasopressor-therapy withdrawal in septic shock.14,15 Finally, our study establishes that a short corticotropin test performed at early onset of septic shock is useful for identifying patients that could most benefit from replacement therapy with corticosteroids. However, it has to be stressed that the time required to obtain the results largely depends on the method used to measure cortisol (eg, enzymatic method, radioimmunoassay) and therefore that treatment should be started as soon as the test has been completed.\n\nThe sample size was calculated to detect a difference of 20% between the 2 groups of nonresponders on the 28-day mortality rate using a 1-sided formulation. Such a formulation was chosen because the preliminary reports that were available at the planning phase of the study22,23 had shown that for several days patients tolerated well 200 to 300 mg of hydrocortisone daily, and we had no interest in formally demonstrating a hypothetical deleterious effect of corticosteroids. However, as recommended by the 9th International Conference on Harmonization, at the time of analysis, all tests were performed using a 2-sided formulation and all reported P values were 2-sided. The sample size was also computed based on the assumptions of a mortality rate of 95% in the nonresponder placebo subgroup and a frequency of nonresponders of 40% in the population of patients with septic shock. In fact, the mortality rate in the nonresponder placebo subgroup (63%) was much lower than expected compared with the reports that were available at the planning phase of the study7,22 and with the hypothesis that patients with adrenal insufficiency would very likely die without hormone replacement. Conversely, the proportion of nonresponders (77%) was much higher than expected and the resulting increase in the sample size of nonresponders (from 108 to 229) may have favored the detection of a lower difference (10%) than expected between the 2 groups.\n\nSeveral differences between the design of this positive study and previous negative studies28-33 deserve comment. First, our trial was focused on a very specific population who were presumed to benefit from corticosteroids because of relative adrenal insufficiency. Second, low doses of a combination of the natural hormone hydrocortisone and fludrocortisone were used (as recommended to treat adrenal insufficiency)16 rather than high doses of a synthetic glucocorticoid compound. The addition of fludrocortisone to hydrocortisone was justified because primary adrenal insufficiency\n######################\nOutput:", "parameters": {"model": "gpt-4o", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}